In its preliminary statement on 2021 results released this week, Kerry Group reports a 5.7% increase in group revenue to €7.4bn which was achieved with an 8% growth in volume for 2021.
This left an EBITDA of €1.1bn, a margin of 14.7%.
Kerry withdrew from production of consumer foods in 2021, selling that part of the business to Pilgrim’s Pride, which is controlled by JBS.
ADVERTISEMENT
Kerry acquisitions included Niacet, a global leader in food technology and it completed the purchase of National Vinegar Company.
In health and bio-pharma, Kerry reached agreement for the acquisition of Natreon and added to its biotechnology capabilities with the acquisition of Enmex and has further deals in the pipeline post year-end.
In emerging markets, Kerry acquired Afribon to join its other businesses in east Africa and a further acquisition is in process in Malaysia post year-end. Net capital expenditure for the year was €315m.
Register for free to read this story and our free stories.
This content is available to digital subscribers and loyalty code users only. Sign in to your account, use the code or subscribe to get unlimited access.
The reader loyalty code gives you full access to the site from when you enter it until the following Wednesday at 9pm. Find your unique code on the back page of Irish Country Living every week.
CODE ACCEPTED
You have full access to the site until next Wednesday at 9pm.
CODE NOT VALID
Please try again or contact support.
In its preliminary statement on 2021 results released this week, Kerry Group reports a 5.7% increase in group revenue to €7.4bn which was achieved with an 8% growth in volume for 2021.
This left an EBITDA of €1.1bn, a margin of 14.7%.
Kerry withdrew from production of consumer foods in 2021, selling that part of the business to Pilgrim’s Pride, which is controlled by JBS.
Kerry acquisitions included Niacet, a global leader in food technology and it completed the purchase of National Vinegar Company.
In health and bio-pharma, Kerry reached agreement for the acquisition of Natreon and added to its biotechnology capabilities with the acquisition of Enmex and has further deals in the pipeline post year-end.
In emerging markets, Kerry acquired Afribon to join its other businesses in east Africa and a further acquisition is in process in Malaysia post year-end. Net capital expenditure for the year was €315m.
If you would like to speak to a member of our team, please call us on 01-4199525.
Link sent to your email address
We have sent an email to your address. Please click on the link in this email to reset your password. If you can't find it in your inbox, please check your spam folder. If you can't find the email, please call us on 01-4199525.
ENTER YOUR LOYALTY CODE:
The reader loyalty code gives you full access to the site from when you enter it until the following Wednesday at 9pm. Find your unique code on the back page of Irish Country Living every week.
SHARING OPTIONS